Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All lufotrelvir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchLufotrelvirLufotrelvir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/​TICO Treatment Trial)

Grandits et al., NCT05780541, NCT05780541
Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -22% Improvement Relative Risk Discharge 44% Lufotrelvir  Grandits et al.  LATE TREATMENT  DB RCT Is late treatment with lufotrelvir beneficial for COVID-19? Double-blind RCT 58 patients in multiple countries Trial underpowered to detect differences c19early.org Grandits et al., NCT05780541, February 2024 Favorslufotrelvir Favorscontrol 0 0.5 1 1.5 2+
RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.
risk of death, 21.9% higher, RR 1.22, p = 0.77, treatment 9 of 32 (28.1%), control 6 of 26 (23.1%), day 90.
risk of no hospital discharge, 43.8% lower, RR 0.56, p = 0.11, treatment 9 of 32 (28.1%), control 13 of 26 (50.0%), NNT 4.6, day 90.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Grandits et al., 9 Feb 2024, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 1 author, trial NCT05780541 (history).
This PaperLufotrelvirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit